NAFLD in patients with schizophrenia: early detection should be conducted

ndividuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical...
PUBLISHED IN: J Clin Psychopharmacol 2021

Commentary

Individuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical records of 253 patients with schizophrenia/schizoaffective disorder who received an abdominal echography.

NAFLD was detected in 108 patients (42.7%). Of these, 13 patients showed signs of fibrosis.

Body mass index, the total dose of antipsychotic drugs that carry a risk of metabolic syndrome, and the total dose of antipsychotic drugs that carry a risk of hyperprolactinaemia were significantly associated with NAFLD. Importantly, the risk in younger female patients may be specific to patients with schizophrenia compared with the general population.the authors, this finding should trigger awareness of non-cardiac comorbidities in patients with pulmonary hypertension.

Share the article
Avatar photo

Dr. D. Beard

DR. D. BEARD is specialist of Nash Pathology

Articles: 191

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES